CSPC Pharmaceutical Group Ltd
Company Profile
Business description
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
Contact
No.896 Zhongshandong Street
Gaoxin District
Hebei Province
Shijiazhuang050035
CHNT: +86 31187037015
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
19,700
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
stocks
What happens if Tesla and SpaceX merge?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.00 | 28.00 | 0.31% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,745.10 | 495.81 | 2.04% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,565.58 | 2,348.31 | 3.66% |
| NZX 50 Index | 13,334.79 | 132.63 | 1.00% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,802.10 | 28.60 | 0.33% |
| SSE Composite Index | 4,040.84 | 53.82 | 1.35% |